[Interpretations of laboratory test data on serum protein binding]

Area of Science:

• Biochemistry
• Pharmacology
• Clinical Chemistry

Context:

• Drug binding to serum proteins, primarily human serum albumin (HSA) and alpha1-acid glycoprotein (AGP), significantly influences drug efficacy and disposition.
• HSA and AGP possess multiple binding sites, each susceptible to modulation by endogenous substances.
• Laboratory tests routinely measure key endogenous substances that interact with these proteins.

Purpose:

• To elucidate the impact of endogenous substances, measurable via standard laboratory tests, on the binding capacities of HSA and AGP.
• To correlate changes in concentrations of free fatty acids (FFA), bilirubin, and uremic toxins (e.g., CMPF, IA, IS, HA) with alterations in drug-protein binding.
• To establish a framework for interpreting laboratory data from a pharmaceutical perspective concerning protein binding.

Summary:

• Both human serum albumin (HSA) and alpha1-acid glycoprotein (AGP) are key serum proteins involved in drug binding.
• Endogenous substances like free fatty acids (FFA), bilirubin, and uremic toxins (CMPF, IA, IS, HA) modulate the binding capacities of specific sites on HSA and AGP.
• FFA enhances site I binding while decreasing site II; bilirubin decreases site I binding; CMPF decreases site I binding; IA, IS, and HA inhibit site II binding.

Impact:

• Monitoring protein binding capacities through laboratory tests offers a pharmaceutical interpretation of endogenous substance concentrations.
• This understanding can refine drug dosage and predict drug behavior in patients with altered physiological conditions.
• Provides a basis for personalized medicine by considering individual variations in protein binding due to endogenous factors.